Susan Galbraith, Executive VP, Oncology R&D, AstraZeneca
April 12, 2022 02:11 PM EDTUpdated April 13, 09:07 AM
R&D

As­traZeneca’s on­col­o­gy R&D chief Su­san Gal­braith high­lights their next-gen prospects at #AACR22

John Carroll

Editor & Founder

As­traZeneca’s turn­around sto­ry rests on the suc­cess of 3 big can­cer drugs: Lyn­parza, Tagris­so and more re­cent­ly En­her­tu. So what’s the fu­ture all about? …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

Califf, on his way out at FDA, pre­dicts agency tug-of-war be­tween Ra­maswamy and RFK Jr.

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

A service from the Financial Times